Antifungal activity of liriodenine on clinical strains of Cryptococcus neoformans and Cryptococcus gattii species complexes

Adriele Dandara Levorato-Vinche1,*, Marcia de Souza Carvalho Melhem2,3, Lucas Xavier Bonfietti2, Iván de-la-Cruz-Chacón4, Carmen Silvia Fernandes Boaro5, Alexandre Todorovic Fabro6, Gisela Ferreira5, Julhiany de Fátima da Silva1, Daniela Carvalho dos Santos7, Beatriz Aparecida Soares Pereira1, Camila Marçon1, Lariza Maza1, Lidia Raquel de Carvalho5, Rinaldo Poncio Mendes1

1Department of Infectology, Dermatology, Diagnostic Imaging and Radiotherapy, Botucatu Medical School (FMB), São Paulo State University (UNESP), Botucatu, SP, Brazil.
2Mycology Unit, Adolfo Lutz Institute, Public Health Reference Laboratory, Secretariat of Health of the State of São Paulo, São Paulo, SP, Brazil.
3Medical School, Federal University of Mato Grosso do Sul, Campo Grande, MS, Brazil.
4Instituto de Ciencias Biológicas, Universidad de Ciencias y Artes de Chiapas, Tuxtla Gutierrez, Chiapas, Mexico.
5Department of Biostatistics, Plant Biology, Parasitology and Zoology, Botucatu Biosciences Institute, São Paulo State University (UNESP), Botucatu, SP, Brazil.
6Department of Pathology and Legal Medicine, Ribeirão Preto Medical School, University of São Paulo (USP), Ribeirão Preto, SP, Brazil.
7Department of Structural and Functional Biology, Botucatu Biosciences Institute, São Paulo State University (UNESP), Botucatu, SP, Brazil.

Keywords:
Liriodenine
Yeast
Fungi
Fungal cell ultrastructure
Cryptococcus spp.
Time-kill methodology

Abstract
Background: Cryptococcal meningitis continues to present high incidence among AIDS patients. The treatment of choice is the synergistic combination of flucytosine (5-FC) with amphotericin B deoxycholate (AmBd) or its lipid formulations. However, 5-FC is unavailable in many countries and AmB demands hospitalization. The combination of AmB with the fungistatic fluconazole (FLC) or the use of high FLC daily doses alone became the choice. Nonetheless, sterilization of cerebrospinal fluid is delayed with FLC monotherapy, mainly with high fungal burden. These findings suggest the search for new antifungal compounds, such as liriodenine. Methods: Liriodenine antifungal activity was evaluated by three procedures: determining the minimum inhibitory concentration (MIC) on 30 strains of the Cryptococcus neoformans (C. neoformans) complex and 30 of the Cryptococcus gattii (C. gattii) complex, using EUCAST methodology and amphotericin B deoxycholate as control; performing the time-kill methodology in two strains of the C. neoformans complex and one of the C. gattii complex; and injury to cryptococcal cells, evaluated by transmission electron microscopy (TEM). Liriodenine absorption and safety at 0.75 and 1.50 mg.kg⁻¹ doses were evaluated in BALB/c mice. Results: Liriodenine MICs ranged from 3.9 to 62.5 μg.mL⁻¹ for both species complexes, with no differences between them. Time-kill methodology confirmed its concentration-dependent fungicidal effect, killing all the strains below the limit of detection (33 CFU.mL⁻¹) at the highest liriodenine concentration (32-fold MIC), with predominant activity during the first 48 hours. Liriodenine induced severe
Cryptococcus alterations – cytoplasm with intense rarefaction and/or degradation, injury of organelles, and presence of vacuoles. Liriodenine was better absorbed at lower doses, with no histopathological alterations on the digestive tract. **Conclusion:** The fungicidal activity confirmed by time-kill methodology, the intense *Cryptococcus* injury observed by TEM, the absorption after gavage administration, and the safety at the tested doses indicate that the liriodenine molecule is a promising drug lead for development of anticryptococcal agents.

**Background**

The increased incidence of fungal infections, mainly in immunosuppressed patients, and the emergence of resistant isolates in many countries worldwide for all available compounds, except amphotericin B (AmB), demonstrate the importance of looking for new antifungal compounds, mainly those recommended for treatment of systemic diseases [1, 2]. Cryptococcosis is a systemic mycosis caused by encapsulated and non-fermentative yeasts of the *Cryptococcus neoformans* (*C. neoformans*) and *Cryptococcus gattii* (*C. gattii*) species complexes [3]. The lungs are the primary portal of entry and focus of this infection, but life-threatening meningitis is its main clinical manifestation, including in AIDS patients [4, 5]. Treatment of cryptococcal meningitis is carried out with the synergistic combination of flucytosine with AmBd or its lipid formulations. Nonetheless, flucytosine is unavailable in many countries, and AmB demands hospitalization, leading to the use of the combination AmB and fluconazole (FLC) for the initial treatment in several countries such as Brazil, or the use of higher doses of FLC as it is in many African countries [6]. Since FLC is fungistatic and causes a slow clearance of the fungus, other regimens and/or combinations with immunomodulators have been evaluated [6–8].

A number of plants produce molecules with antimicrobial activity, including several species of the Annonaceae family, which produce benzylisoquinoline alkaloids [9]. One of the most common ones is liriodenine, an alkaloid aporphine type found in around 90 genera and 300 Annonaceae species [10, 11] with activity on fungi, bacteria, and protozoa [12–17].

Levorato-Vinche et al. [18] evaluated the *in vitro* antifungal activity of liriodenine on agents of systemic mycoses, and it showed a minimum inhibitory concentration (MIC) of 62.5 μg.mL⁻¹ on most of the isolates. Moreover, its activity was fungicidal on susceptible isolates.

The present study aimed at evaluating liriodenine antifungal activity on isolates of both *C. neoformans* and *C. gattii* species complexes using the time-kill curve and the analysis of cell alterations by electron microscopy.

**Methods**

**Antifungal compounds**

AmBd (Sigma Chemical Company, St. Louis, MO, USA) and liriodenine were used for MIC testing. Moreover, a time-kill evaluation of liriodenine was performed.

**Cryptococcal susceptibility testing**

The *in vitro* susceptibility to liriodenine and to AmBd was evaluated by the broth microdilution method, according to...
the European Committee on Susceptibility Testing (EUCAST) [21]. The antifungal epidemiologic cutoff values (ECOFFs) and clinical breakpoints were proposed according to the EUCAST E. Def 7.3 document (European Committee on Antimicrobial Susceptibility Testing), and by using colorimetric indicators [22].

Serial dilutions of the stock solution using RPMI-1640 as diluent were performed, and 10 concentrations of liriodenine ranging from 0.97 to 500 μg.mL⁻¹ were obtained. Volumes of 100 μL of each concentration were distributed in microplates with 96 wells. AmBd was included as a positive control in 10 concentrations from 0.03 to 16 μg.mL⁻¹. The inocula of the fungal cells were adjusted to a final concentration of 1·5 × 10⁸ cells/mL, and 100 μL were added to each well containing either liriodenine or AmBd, and to the control wells without antifungal compounds. The plates were incubated at 35 °C ± 2 °C for 48 h, and then the reading was performed with a microdilution plate reader under 450 nm wavelength. The antifungal concentration that elicited an relative absorbance ≤ 50% or < 90% of that observed in the negative control well (without antifungal compound) was considered the MIC of liriodenine and AmBd, respectively. All the tests were carried out in triplicate [21].

**Time-kill studies with liriodenine**

The time-kill studies were conducted with two strains (strain 32 and strain 57) of the C. neoformans complex and one (strain 17) of the C. gattii complex, according to the procedures of Klepser et al. [23] and Silva et al. [24]. Initially, the isolates were subcultured on potato dextrose agar plates. Individual colonies (≥ 1 mm) from 48-h culture were suspended in 10-mL buffered RPMI 1640 with 2% glucose and L-glutamine medium. Isolates were grown overnight with shaking at 35 °C. The initial inoculum was adjusted to 0.5 McFarland turbidity standard (10⁶ CFU.mL⁻¹). One milliliter of the adjusted fungal suspension was then added to either a 9-mL MOPS-buffered RPMI medium alone (control) or a solution of culture medium containing liriodenine. Liriodenine was tested in eight concentrations calculated as multiples of the MIC values (0.5×, 1×, 2×, 3×, 4×, 8×, 16× and ≤ 0.05. pIn vivo evaluation of absorption and toxicity

**Animals**

Four isogenic albino male BALB/c mice, five to seven weeks of age and 25 g average weight, were obtained from the husbandry of the Experimental Laboratory of Infectious and Parasitic Diseases of Botucatu Medical School, São Paulo State University (UNESP), Botucatu Biosciences Institute (São Paulo state, Brazil). The animals were kept in boxes containing two animals on average, with a bed of pressure-treated wood shavings, in an environment ranging 23-25 °C, with lighting controlled by electromechanical time switch, that is, 12 h with the light on and 12 h in the dark. They received filtered water and commercial mice diet ad libitum.

**Liriodenine preparation and administration in uninfected mice**

Liriodenine was dissolved in 4% DMSO. For the preparation of the doses 0.75 and 1.50 mg.kg⁻¹, 1.5 and 3.0 mg of liriodenine, respectively, 0.240 mL of 4% DMSO were added. Liriodenine was given by gavage in a single dose at 12:00 a.m. Each animal received 0.120 mL of the liriodenine-containing solution.

**Statistical analysis**

The comparison between the MIC values of different species and the antifungal compounds was carried out using the Mann-Whitney test. The correlation of MIC between antifungal compounds was performed by the Spearman rank correlation coefficient. Statistical tests were performed by using SAS (SAS Institute, Cary, NC, USA). Significance was set up at $p \leq 0.05$.
The doses used were defined based on the results of the in vitro sensitivity test [18]. Two uninfected mice received 0.75 mg.kg⁻¹ and other two 1.50 mg.kg⁻¹ of liriodenine in a single dose.

**Blood collection and euthanasia of the mice**

The animals were submitted to blood collection and euthanasia six and 12 h after liriodenine administration. Blood samples were collected from each animal by cardiac puncture to determine the serum levels of liriodenine.

Mice were initially anesthetized and killed with 0.08 μL of a solution containing 24 μL ketamine, 32 μL xylosin, and 24 μL distilled water, which was administered intraperitoneally with the aid of a 1.0 mL disposable syringe. After sedation, the blood was collected by cardiac puncture using a 1.0 mL syringe and a 25 × 7-gauge needle. The blood was transferred to a sterile test tube without anticoagulants and, subsequently, centrifuged at 3.500 rpm in a Revan Cycle C I centrifuge.

**Serum dosage of liriodenine**

The serum samples from the mice were diluted in 15 mL deionized water to increase the volume of the working solution. In order to extract the fat present in the serum, the mixture was placed in a separatory funnel with 10 mL hexane, from which the aqueous phase was collected and then adjusted to 9.5 pH with saturated solution of Na₂CO₃. After that, it was placed in a separatory funnel with 10 mL chloroform, and the chloroform phase containing the liriodenine was then collected. For the identification and quantification of the liriodenine, the sample was kept to stand until the chloroform was completely evaporated, then dissolved in methanol and analyzed in High Performance Liquid Chromatography (HPLC), according to the specifications modified by de-La-Cruz-Chacón et al. [16, 17]. The samples were eluted in isocratic mode – 80% methanol (J. T. Baker, HPLC grade) and 20% ultrapure water – and the pH was adjusted to 3.0 with acetic acid. The flow rate of the mobile phase was 1.0 mL/min and the total time was 15 min, with 254 nm wavelength and 20 μL injection volume. The compartment of the chromatographic column oven was programmed to 30 °C. The equipment used was an HPLC (Thermo Scientific Dionex Ultimate 3000) equipped with a Uv-VIS detector, an automatic injector with an oven and a four-channel pump with built-in degasser, and LUNA* 5 μm C18 (250 × 4.6 mm) column by Phenomenex [28].

The serum level of each sample was measured in triplicate, using the average of the concentrations found.

**Histopathological evaluation**

The histopathological examination of the intestines was performed in all animals. The intestines were collected and fixed in formalin for 48 h, then transferred to 70% alcohol and embedded in paraffin. Cuttings were performed, and afterwards, the slides were stained with hematoxylin and eosin (H&E).

**Results**

**Minimum inhibitory concentrations (MICs)**

The MIC of liriodenine ranged from 3.9 μg.mL⁻¹ to 62.5 μg.mL⁻¹ for *C. neoformans* as well as for *C. gattii* (Figure 1). MIC₉₀ was 31.25 μg.mL⁻¹ for both species. All the strains were inhibited to liriodenine and presented no differences in susceptibility regarding the species (*p* > 0.05). In addition, the low MICs of AmB did not differ between the species (*p* > 0.05). MIC₉₀ was 0.125 μg.mL⁻¹ for both species, and all strains showed high susceptibility to AmB.

**Time-kill studies**

Figures 2, 3 and 4 show time-kill curves for liriodenine using three strains exposed to four different agent concentrations and one untreated control of each strain. Liriodenine induced a fungicidal effect in all three strains, yet the onset of the fungicidal activity depended on the tested concentration and differed among

![Figure 1. Minimum inhibitory concentrations (MICs) of liriodenine (LRD) and amphotericin B (AmB) for 30 strains of the Cryptococcus neoformans complex and 30 strains of the Cryptococcus gattii complex, determined by broth microdilution method. Results as median and interquartile intervals, as well as geometric mean. The Mann-Whitney U rank test. Comparison of MICs as to Cryptococcus complex, (A) LRD: *C. neoformans*: 15.62 [15.62; 31.25], *C. gattii*: 31.25 [15.62; 31.25], *p* = 0.30, (B) AmB: *C. neoformans*: 0.06 [0.06; 0.06], *C. gattii*: 0.06 [0.06; 0.13], *p* = 0.45.](image-url)
Figure 2. Time-kill curves for lireodenine against strain 17 of Cryptococcus gattii complex. Eight doubling dilutions are plotted, the highest concentration corresponds to 32 × MIC as measured with the EUCAST microdilution method, and the blue line represents growth in absence of lireodenine. The compound was added at timepoint 0 and monitored until 72 h. The limit of detection in the assay was 33 CFU/mL. CFU: colony forming units; MIC: minimum inhibitory concentration.

Figure 3. Time-kill curves for lireodenine against strain 57 of Cryptococcus neoformans complex. Eight doubling dilutions are plotted, the highest concentration corresponds to 32 × MIC as measured with the EUCAST microdilution method, and the blue line represents growth in absence of lireodenine. The compound was added at timepoint 0 and monitored until 72 h. The limit of detection in the assay was 33 CFU/mL. CFU: colony forming units; MIC: minimum inhibitory concentration.
Figure 4. Time-kill curves for lireodenine against strain 32 of Cryptococcus neoformans complex. Eight doubling dilutions are plotted, the highest concentration corresponds to 32 × MIC as measured with the EUCAST microdilution method, and the blue line represents growth in absence of lireodenine. The compound was added at timepoint 0 and monitored until 72 h. The limit of detection in the assay was 33 CFU/mL. CFU: colony forming units; MIC: minimum inhibitory concentration.

the strains. All strains were killed to below the limit of detection (33 CFU.mL⁻¹), at the highest lireodenine concentration (32-fold MIC). The strains experienced the most killing during the first 48 h at high antimicrobial concentrations. For strains 37 and 32, the fungicidal activity decreased at lower concentrations.

Transmission electron microscopy

Transmission electron microscopy (TEM) of untreated cryptococcal cells revealed round shape with regular contours, uniformly thick walls, and a polysaccharide capsule. The organelles were preserved and intact, enabling the detection of free ribosomes, a discrete rough endoplasmic reticulum, multivesicular bodies, vacuoles of a heterogeneous material and various sizes, and a few lipid droplets. Ligaments between cells and their buds were also demonstrated (Figures 5A and 5B).

However, lireodenine-treated cryptococcal cells presented significantly altered morphology. In both species complexes, the cytoplasm showed intense rarefaction and/or degradation, injury of organelles, vacuoles, or other structures, suggesting death of the microorganism (Figures 5B, 5C, 5E and 5F).

In vivo evaluation of absorption and toxicity

Clinical observation and histopathological analysis

Prior to the administration of lireodenine, all animals had shiny hair, and had been calm eating regularly. Such conditions did not change with the administration of lireodenine.

Nevertheless, 12 h after the administration of lireodenine, the mice that had received the dose of 1.50 mg.kg⁻¹ of body weight had abdominal distension; the laparotomy revealed the presence of large amounts of intestinal gas (Additional file 1).

These findings were not observed in animals that received lireodenine at the dose of 0.75 mg.kg⁻¹ of body weight.

The cross-sectional histological analyses of the intestines in all the animals, which were observed using light microscopy, showed no pathological alterations with either of the doses administered or in either of the two different moments of euthanasia (Figure 6).

Figure 6. Intestinal histomorphology of BALB/c mice after administration of lireodenine by gavage. Note the absence of pathological changes at different doses (0.75 and 1.50 mg.kg⁻¹) of lireodenine and different moments of euthanasia (6 and 12 h of administration) [H&E; 5XX].
Figure 5. Transmission electron microscopy of Cryptococcus neoformans and Cryptococcus gattii species complexes. (A) Untreated Cryptococcus neoformans species complex cells. (B, C) Liriodenine-treated Cryptococcus neoformans species complex cells at a concentration of 31.25 µg.mL⁻¹. (D) Untreated Cryptococcus gattii species complex cells. (E, F) Liriodenine-treated Cryptococcus gattii species complex cells at a concentration of 62.5 µg.mL⁻¹. PM: plasma membrane; PC: polysaccharide capsule; MVB: multivesicular bodies; VA: vacuoles; LI: lipids; RER: rough endoplasmic reticulum; CR: cytoplasmic rarefaction; cell membrane irregularity.
Serum dosage of liriodenine

Liriodenine was detected in the serum of both mouse groups that had received it at the doses of 0.75 mg.kg⁻¹ and 1.50 mg.kg⁻¹ of body weight, confirming the absorption of this substance after administration by gavage (Figure 7).

However, serum levels of liriodenine showed different behavior due to the time of administration, according to the dose used in the mice: the ones that had received 0.75 mg.kg⁻¹ presented an increase in concentration over time, while the opposite was observed in animals to which 1.50 mg.kg⁻¹ had been administered.

Figure 7. Serum levels of liriodenine were observed at 6 and 12 h after the administration by gavage of both doses of 0.75 and 1.50 mg.kg⁻¹ of body weight. Data from one animal per dose at the time. The serum level is the average of three repetitions performed in each sample.

Discussion

In spite of the well-conducted studies on the treatment of cryptococcal meningitis, many questions still remain unanswered in the clinical practice, stimulating the investigation of new compounds, such as liriodenine [6–8, 29, 30]. The choice of this compound was based on some previous information: (a) liriodenine is extracted from Annona mucosa, a plant available in the Brazilian region where our university is located; (b) liriodenine extraction was performed in this university; (c) its chemical composition is known, making it easier to have a possible future production and modification of the molecule; (d) the literature review revealed some antimicrobial activity; (e) our previous study showed its activity on some fungi, mainly from the Cryptococcus genus [18].

Antifungal susceptibility testing (AST) has become a powerful tool in the choice and management of treatment of many systemic fungal diseases. Therefore, the protocols used in AST should be very well standardized and validated. The ones used in this study were RPMI 1640 buffered to a pH 7.0 with MOPS, incubation of time-kill samples at 35 °C with agitation, effect on antifungal carryover and evaluation for at least 24 hours compliant to Klepser et al. [23] standardization, being most of them confirmed by Zaragoza et al. [31]. In addition, the correlations between AST and clinical response are poor with MIC, increase a little with minimum fungicidal concentration (MFC), and are much better with the time-kill methodology [32], which was carried out in this study. As already described for the fungicidal drug AMB, isolates can show different profiles in the time-kill methodology that are impossible to identify only by MIC [24–26]. Future studies on pharmacokinetics and pharmacodynamics associated with time-kill data should improve the knowledge on the in vivo activity of liriodenine.

The present study demonstrated fungicidal activity of liriodenine on fungi of the C. neoformans and C. gattii species complexes, showing MIC values ranging from 3.9 to 62.5 µg.mL⁻¹. Such results are similar to those obtained by Cruz et al. [33], who observed the activity of the synthetic 8-nitrohormone on eight strains of fungi from the Cryptococcus genus, with MICs of 40 µg.mL⁻¹; however, the authors did not evaluate whether the compound presented a fungistatic or fungicidal effect.

The MICs of liriodenine observed in the present study were lower than those showed by the fatty acid methyl esters extracted from seeds of Annona cornifolia (> 500 µg.mL⁻¹) [34], and they were also lower when compared to the essential oil and its major components linalool and geraniol extracted from Ocimum basilicum var. Maria Bonita, whose MICs ranged from 156 to 2500 µg.mL⁻¹ [35]. Nevertheless, higher activity was found with maytenin and pristimerin, extracted from Maytenus ilicifolia (Celastraceae), when evaluated against five isolates of the Cryptococcus genus, showing MICs and MFCs ranging from 0.48 to 3.90 µg.mL⁻¹ and from 0.97 to 7.81 µg.mL⁻¹, respectively [36]. Punicalagin, a hydrophilic tannin extracted from Lagoenesis pacari A. St.-Hil (Lythraceae), presented a fungistatic effect on fungi of the C. neoformans complex, with MICs ranging from 0.5 to 4.0 µg.mL⁻¹, which are values lower than those observed in the present study. However, its fungicidal activity was demonstrated at 256 µg.mL⁻¹ [37].

The previous findings with liriodenine based on MFC [18] were confirmed by the present study, in which the time-kill methodology was carried out. In addition, the intense morphological alterations demonstrated by TEM – suggestive of killed cryptococcal cells – seem to justify liriodenine fungicidal activity. To the best of our knowledge, this is the second study showing the effect of an antifungal compound on cryptococcal cells using TEM.

The mechanism of action of liriodenine has yet to be demonstrated. The results of this study could be taken into consideration, contributing to fill this gap. The in vitro and in vivo inhibition of the topoisomerase II enzyme of the DNA, like the quinolones, suggest an interference in the RNA and protein synthesis [38]. Furthermore, melanin, produced by the action of phenol oxidase on L-DOPA [39, 40], is a virulence factor for fungi of the Cryptococcus genus for protecting them from oxidative stress, phagocytosis, the action of antifungal compounds, as well as for modifying the host immune response [41–46]. As liriodenine inhibits the melanin synthesis in PC-12 cells, this anti-melanin activity could play a role in its anticytotoxic activity [47]. Finally, liriodenine causes an imbalance in the iron cell homeostasis, leading to the accumulation of the mitochondrial...
iron, a decrease in the number of iron enzymes, and an increase in the oxidative stress, which causes fungal death [48].

Ultrastructural studies of antifungal compound actions on Cryptococcus cells are scarce [49–51]. Subinhibitory concentrations, from 0.125 to 0.5 of MIC either of AmB or of fluconazole, alter cell and capsule size, and cell shape at scanning electron microscopy [49]. Terbinafine, a fungistatic compound, causes detachment of the cell membrane from the cell wall, which probably results in membrane impairment, as well as increased cytoplasmic vacuoles that could account for the lipid accumulation and mitochondrial swelling [51]. Some of these findings, including irregularity of cytoplasmic membranes and cytoplasmic vacuoles, are also observed with liriodenine, a fungicidal compound.

The evaluation of liriodenine serum levels after gavage administration suggests better absorption with the lower dose used, 0.75 mg.kg⁻¹, which may be justified by the gas formation determined by the dose of 1.50 mg.kg⁻¹. Thus, the abdominal distension due to gas formation could lead to a reduction in the absorption of liriodenine since the histopathological evaluation with the H&E staining of the intestinal fragments did not reveal any organic lesion. This result prompts the development of further studies on liriodenine or its derivatives as an anticytotoxic compound.

The potential weakness of this study is MIC ₉₀ higher than that observed with AmB. Such finding suggests the investigation of liriodenine derivatives with the same fungicidal activity but with lower MICs, which is ongoing. The best derivatives will progress into the determination of the mechanism of action, pharmacokinetic studies, and combination with other antifungal compounds.

Conclusions
The present in vitro studies of liriodenine on fungi of C. neoformans and C. gattii species complexes demonstrated intense structural alterations of the yeast cells and fungicidal activity when assessed by time-kill methodology. These results suggest that this molecule can be a promising prototype of anticryptococcal compounds. Investigations on modifications of the liriodenine molecule to improve its pharmacological properties and experimental cryptococcal infection are currently ongoing for evaluating the safety and efficacy of this anticytotoxic compound and its derivatives.

Acknowledgments
We thank Rinaldo José Ortiz, from the University Library of Botucatu Campus, UNESP, for organizing the references.

Availability of data and materials
All data generated or analyzed during the study are included in this article.

Funding
ADLV was the recipient of a doctoral scholarship from the Coordination for the Improvement of Higher Education Personnel (CAPES).

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
ADLV and RPM contributed equally to this manuscript. MSCM isolated and identified the Cryptococcus strains. IDLCC and GF carried out the extraction and identification of liriodenine. CSFB performed the serum measurement of liriodenine in mice. ATF conducted the histopathological analysis. ADLV, JFS, BEP and CM conducted the susceptibility testing and time-kill studies. LM carried out the administration of liriodenine and the removal of material for histopathological analysis and serum dosage in mice. DCS performed the transmission electron microscopy. LRC was responsible for the statistical analysis. The article was written by ADLV, MSCM and RPM. All authors read and approved the final manuscript.

Ethics approval
The study was submitted to and approved by the Research Ethics Committee (protocol number 2.257.787) as well as by the Ethics Committee on Animal Research (protocol 127/2017), both from Botucatu Medical School (FMB) of São Paulo State University (UNESP).

Consent for publication
Not applicable.

Supplementary material
The following online material is available for this article:

Additional file 1. BALB/c mice receiving liriodenine by gavage at a concentration of 1.50 mg.kg⁻¹. The euthanasia was performed 12 h after administration of liriodenine. (A1-B1) Mice during the euthanasia. (A2-B2) Intestines removed from the dead animals.

References


